☆ 4.4 Editorial Material

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go

FUTURE ONCOLOGY (2019)

期刊

FUTURE ONCOLOGY

卷 15, 期 19, 页码 2199-2202

出版社

FUTURE MEDICINE LTD

DOI: 10.2217/fon-2019-0217

关键词

atezolizumab; basal-type; genitourinary tumors; immunotherapy; luminal-type; lymphocytes; microbiome; PD-L1; urothelial carcinoma

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan

Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC

Myriam Kossai, Camelia Radulescu, Julien Adam, Anais Dziegielewski, Nicolas Signolle, Mathilde Sibony, Thierry Lebret, Yves Allory, Mathieu Rouanne

Summary: Plasmacytoid UC differs from conventional UC in pathological features and immune expression, but belongs to the luminal subtype and exhibits an inflamed microenvironment. These findings support the inclusion of plasmacytoid variant of UC in clinical trials evaluating immune checkpoint inhibitors monotherapy or combination immunotherapeutic strategies.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

添加到收藏夹

Article Oncology

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade

Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F. Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P. Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A. Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Ruettinger, Jean-Pierre Delord, Aurelien Marabelle

Summary: This phase 1b study evaluated the safety and antitumor activity of the combination of emactuzumab and atezolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile and a significant objective response rate was observed in ICB-experienced NSCLC patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Immunology

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack

Summary: This study found that Gal-3 can enhance the PD-1/PD-L1 immune axis and potentially contribute to immunosuppressive signaling mechanisms within the tumor microenvironment. Additionally, Gal-3 prevents atezolizumab and pembrolizumab from engaging with their respective immune checkpoint receptors. Reversal of this effect with the clinical candidate GB1211 offers a potential enhancing combination therapeutic with anti-PD-1 and -PD-L1 blocking antibodies.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Immunology

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma

Fu-xue Huang, Jun-wan Wu, Xia-qin Cheng, Jiu-hong Wang, Xi-zhi Wen, Jing-jing Li, Qiong Zhang, Hang Jiang, Qiu-yue Ding, Xiao-feng Zhu, Xiao-shi Zhang, Ya Ding, Dan-dan Li

Summary: This study showed that high expression of HHLA2 is associated with better prognosis and improved response to immune checkpoint blockades in melanoma patients. The expression of HHLA2 is also positively correlated with the density of CD8(+) tumor infiltrating lymphocytes.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade

Michael Fehlings, Leesun Kim, Xiangnan Guan, Kobe Yuen, Alireza Tafazzol, Shomyseh Sanjabi, Oliver A. Zill, Deepali Rishipathak, Andrew Wallace, Alessandra Nardin, Siming Ma, Ana Milojkovic, Evan W. Newell, Sanjeev Mariathasan, Mahesh Yadav

Summary: This study found a high frequency of CD57 expression among neoantigen-specific and bulk CD8 T cells in patients responding to atezolizumab. The overlap of T-cell receptor repertoire between peripheral CD57(+) CD8 T cells and tumor-infiltrating lymphocytes suggests that the accumulation of peripheral CD57(+) CD8 T cells reflects an ongoing antitumor T-cell response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Intratumoral CD103+CD8+T cells predict response to PD-L1 blockade

Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patricia de Almeida, Edward E. Kadel, Shravan Madireddi, Amelia Au-Yeung, Chikara Takahashi, Ying-Jiun Chen, Zora Modrusan, Jacqueline McBride, Rhea Nersesian, Ehab A. El-Gabry, Mark D. Robida, Jeffrey C. Hung, Marcin Kowanetz, Wei Zou, Mark McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane Grogan, William E. O'Gorman

Summary: CD8+ tissue-resident memory T (T-RM) cells expressing CD103 (ITGAE) are believed to actively suppress cancer progression, and their presence in tumors may predict response to immunotherapy. This study found that in inflamed tumors, CD103+ CD8+ T-RM cells exhibit a complex phenotype characterized by increased clonal expansion, expression of checkpoint regulators, and cytotoxic proteins, suggesting their involvement in antitumor response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer

Yohei Sekino, Quoc Thang Pham, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Hikaru Nakahara, Kazuhiro Sentani, Naohide Oue, Wataru Yasui, Jun Teishima, Nobuyuki Hinata

Summary: The study revealed that KIFC1 expression is positive in bladder cancer, associated with poor prognosis, basal type BC, TP53 alterations, and increased sensitivity to cisplatin when knocked down. Moreover, KIFC1-positive cases were related to p53-positive cases and poor prognosis in patients treated with cisplatin-based chemotherapy. The results suggest that KIFC1 could serve as a potential biomarker and therapeutic target in bladder cancer.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Review Immunology

Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma

Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu

Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

Yufan Qiu, Yi Yang, Riyao Yang, Chunxiao Liu, Jung-Mao Hsu, Zhou Jiang, Linlin Sun, Yongkun Wei, Chia-Wei Li, Dihua Yu, Jin Zhang, Mien-Chie Hung

Summary: The study reveals that PD-1 can be secreted in an exosomal form by activated T cells and interact remotely with PD-L1. This interaction can attenuate the suppression of tumor-specific cytotoxic T cell activity by PD-L1, restoring tumor surveillance.

ONCOGENE (2021)

添加到收藏夹

Article Pathology

Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma

Xiaohu Chen, Hanbin Chen, Rixu Lin, Yulian Li, Ying Guo, Qi Chen, Yanyan Zhang, Guoping Cai, Mengjun Hu, Guorong Chen

Summary: This study reveals that PD-L1 expression in tumor cells is associated with the corresponding infiltration of T cells, and the combination of T-PD-L1 and I-PD-L1, T-PD-L1 and TILs may serve as relevant markers for determining the prognosis of patients with urothelial carcinoma.

JOURNAL OF CLINICAL PATHOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Maohua Li, Rongqing Zhao, Jianxin Chen, Wenzhi Tian, Chenxi Xia, Xudong Liu, Yingzi Li, Song Li, Hunter Sun, Tong Shen, Wenlin Ren, Le Sun

Summary: Maxatezo, a glycosylated version of the FDA-approved anti-PD-L1 antibody drug Atezolizumab, exhibits improved thermal stability and anti-tumor activity compared to its aglycosylated counterpart. It also shows lower ADCC activity in vivo and a higher tumor growth inhibition rate at the same dose level.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Urology & Nephrology

Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma

Philip Zeuschner, Kerstin Junker

Summary: Despite the approval of multiple immune checkpoint inhibitors for the treatment of genitourinary tumors, there is still a lack of predictive biomarkers. Tumor-infiltrating cells have been associated with therapy response, but the predictive value of the only approved biomarker, PD-L1 immunostaining, for urothelial carcinoma is questionable.

EUROPEAN UROLOGY FOCUS (2022)

添加到收藏夹

Article Immunology

Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer

Ali Ameri, Bahareh Tavakoli-Far, Maryam Rostami, Bahman Abedi Kiasari, Delaram Sakhaei, Omar Saad Ahmed, Fatemeh Forouzani, Yasaman Fazli

Summary: Immune checkpoint inhibitor atezolizumab has shown promising results in treating breast cancer, especially in patients with triple-negative breast cancer (TNBC). By interfering with the binding of PD-L1 ligand, atezolizumab enhances T-cell responses to the tumor and improves treatment outcomes. Clinical trials have demonstrated the efficacy of atezolizumab in PD-L1-positive TNBC patients.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression

Jing Huang, Xiaobo Wang, Bing Li, Shiyu Shen, Ruina Wang, Hongru Tao, Junchi Hu, Jin Yu, Hualiang Jiang, Kaixian Chen, Cheng Luo, Yongjun Dang, Yuanyuan Zhang

Summary: This study found that L-5-hydroxytryptophan (L-5-HTP) can suppress the expression of programmed death-ligand 1 (PD-L1) induced by interferon gamma (IFN-gamma) in tumor cells and has an antitumor effect. L-5-HTP achieves its inhibitory effect on PD-L1 induction by inhibiting the expression of RTK ligands and related signaling pathways. Additionally, L-5-HTP synergizes with PD-1 antibodies to enhance anticancer effects. These findings provide new insights into repurposing L-5-HTP for use in tumor immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis

Matteo Santoni, Francesco Massari, Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli

Summary: This study compared the clinical outcomes of apalutamide and enzalutamide in CSPC patients, and found that apalutamide had better overall survival and safety, while enzalutamide showed better efficacy in the low-volume subgroup.

TUMORI JOURNAL (2023)

添加到收藏夹

Article Cell Biology

Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity

Sean R. Williamson, Ondrej Hes, Kiril Trpkov, Aditi Aggarwal, Abhishek Satapathy, Sourav Mishra, Shivani Sharma, Ankur Sangoi, Liang Cheng, Mahmut Akgul, Muhammad Idrees, Albert Levin, Sudha Sadasivan, Pilar San Miguel Fraile, Joanna Rogala, Eva Comperat, Daniel M. Berney, Stela Bulimbasic, Jesse K. McKenney, Shilpy Jha, Nakul Y. Sampat, Sambit K. Mohanty

Summary: Low-grade oncocytic tumour (LOT) of the kidney is a potential novel tumour type with distinct morphological, immunohistochemical, and genetic characteristics. Tumours in this study were found to have alterations in genes related to the tuberous sclerosis/MTOR pathway, as well as PIK3CA. Further research is needed to determine the clinical implications and differences from other renal cancers.

HISTOPATHOLOGY (2023)

添加到收藏夹

Review Pathology

The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges

Sambit K. Mohanty, Anandi Lobo, Liang Cheng

Summary: The fifth edition of the WHO classification of urinary and male genital organ tumors, published in 2022, incorporated molecular profiling into the classification of urologic tumors. Major changes include the introduction of molecularly well-defined subtypes of renal tumors and the re-categorization of various tumor types. The new classification also recommends the use of the WHO/ISUP grading for all renal cell carcinomas. Furthermore, there are significant nomenclature changes for different tumor entities. Metastatic, hematolymphoid, mesenchymal, melanocytic, soft tissue, and neuroendocrine tumors are discussed separately in dedicated chapters.

HUMAN PATHOLOGY (2023)

添加到收藏夹

Article Anatomy & Morphology

Histopathology of Prostate Cancer and its Precursors

Rodolfo Montironi, Alessia Cimadamore, Roberta Mazzucchelli, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng

Summary: Starting in the mid-1970s, a group of pathologists with a major interest in uropathology was formed. Over the years, the group expanded with the addition of new members, and some members reached retirement age. The collaboration spanned for 45 years, with a focus on the interpretation of prostate cancer and its precursors.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer

Sebastian Foersch, Christina Glasner, Ann-Christin Woerl, Markus Eckstein, Daniel-Christoph Wagner, Stefan Schulz, Franziska Kellers, Aurelie Fernandez, Konstantina Tserea, Michael Kloth, Arndt Hartmann, Achim Heintz, Wilko Weichert, Wilfried Roth, Carol Geppert, Jakob Nikolas Kather, Moritz Jesinghaus

Summary: Researchers developed a multistain deep learning model utilizing artificial intelligence to determine the immunoscore and predict response to neoadjuvant therapy in colorectal cancer patients. The model outperformed other clinical, molecular, and immune cell-based parameters and can serve as a valuable decision-making tool for clinicians.

NATURE MEDICINE (2023)

添加到收藏夹

Editorial Material Pathology

Tumour grading: communication is the key

Murali Varma, Brett Delahunt, Liang Cheng, Runjan Chetty, Eva Comperat, Vikram Deshpande, Lars Egevad, Theodorus H. van der Kwast, Antonio Lopez-Beltran, W. Glenn McCluggage

JOURNAL OF CLINICAL PATHOLOGY (2023)

添加到收藏夹

Correction Multidisciplinary Sciences

CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression (vol 13, 73, 2023)

Miriam Saponaro, Sina Flottmann, Markus Eckstein, Oliver Hommerding, Niklas Kluemper, Dillon Corvino, Sana Hosni, Anja Schmidt, Nicolas Moenig, Doris Schmidt, Joerg Ellinger, Marieta Toma, Glen Kristiansen, Tobias Bald, Andrea Alimonti, Manuel Ritter, Michael Hoelzel, Abdullah Alajati

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Contrast-Enhanced Multispectral Optoacoustic Tomography for Functional Assessment of the Gastrointestinal Tract

Lars-Philip Paulus, Adrian Buehler, Alexandra L. Wagner, Roman Raming, Joerg Juengert, David Simon, Koray Tascilar, Alexander Schnell, Ulrich Rother, Markus Eckstein, Werner Lang, Andre Hoerning, Georg Schett, Markus F. Neurath, Maximilian J. Waldner, Regina Trollmann, Joachim Woelfle, Sarah E. Bohndiek, Adrian P. Regensburger, Ferdinand Knieling

Summary: The use of multispectral optoacoustic tomography (MSOT) with indocyanine green (ICG) as a fluorescent dye allows real-time imaging and functional assessment of the gastrointestinal tract. This approach provides a non-ionizing and translatable method for clinical diagnosis.

ADVANCED SCIENCE (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Transrectal Absorber Guide Raster-Scanning Optoacoustic Mesoscopy for Label-Free In Vivo Assessment of Colitis

Adrian Buehler, Emma Brown, Lars-Philip Paulus, Markus Eckstein, Oana-Maria Thoma, Mariam-Eleni Oraiopoulou, Ulrich Rother, Andre Hoerning, Arndt Hartmann, Markus F. F. Neurath, Joachim Woelfle, Oliver Friedrich, Maximilian J. J. Waldner, Ferdinand Knieling, Sarah E. E. Bohndiek, Adrian P. P. Regensburger

Summary: Optoacoustic imaging enables microscale imaging of endogenous chromophores and has shown potential in identifying superficial microvascular changes associated with human skin pathologies. Raster-scanning optoacoustic mesoscopy has been used to image vascular structures in the gastrointestinal tract in animal models, but accurate localization of intra-abdominal organs is still challenging. This study presents the development of a novel transrectal absorber guide for optoacoustic mesoscopy to enable accurate transabdominal localization and assessment of colonic vascular networks. The potential of this technique is demonstrated through its application in colitis models in mice, highlighting its potential as a monitoring tool for inflammatory bowel diseases.

ADVANCED SCIENCE (2023)

添加到收藏夹

Review Oncology

Efficacy of Different Bacillus of Calmette-Guerin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis

Francesco Del Giudice, Vincenzo Asero, Eugenio Bologna, Carlo Maria Scornajenghi, Dalila Carino, Virginia Dolci, Pietro Viscuso, Stefano Salciccia, Alessandro Sciarra, David D'Andrea, Benjamin Pradere, Marco Moschini, Andrea Mari, Simone Albisinni, Wojciech Krajewski, Tomasz Szydelko, Bartosz Malkiewicz, Lukasz Nowak, Ekaterina Laukhtina, Andrea Gallioli, Laura S. Mertens, Gautier Marcq, Alessia Cimadamore, Luca Afferi, Francesco Soria, Keiichiro Mori, Karl Heinrich Tully, Renate Pichler, Matteo Ferro, Octavian Sabin Tataru, Riccardo Autorino, Simone Crivellaro, Felice Crocetto, Gian Maria Busetto, Satvir Basran, Michael L. Eisenberg, Benjamin Inbeh Chung, Ettore De Berardinis

Summary: In this systematic review and meta-analysis, the cumulative bladder cancer (BC) recurrence rates and efficacy profile of different Bacillus of Calmette-Guerin (BCG) strains were compared. The study found that BCG Tokyo 172 had the lowest recurrence rate among studies with <= 3-year recurrence-free survival (RFS). No significant difference was observed among strains in >3-year RFS outcomes. The genetically different BCG strains RIVM, Tice, and Tokyo 172 showed some potential enhanced benefits.

CANCERS (2023)

添加到收藏夹

Article Medicine, General & Internal

Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer

Alessandra Borgheresi, Andrea Agostini, Francesca Sternardi, Elisa Cesari, Fiammetta Ventura, Letizia Ottaviani, Rocco Francesco Delle Fave, Eugenio Pretore, Alessia Cimadamore, Alessandra Filosa, Andrea Benedetto Galosi, Andrea Giovagnoni

Summary: This study aimed to evaluate the presence of perivesical venous ectasia as an indirect sign of lymph node involvement in bladder cancer patients. The results showed that LN short axis > 5 mm, LN enhancement, and Largest Venous Diameter > 3 mm were significantly correlated with positive lymph nodes at pathology. Largest Venous Diameter > 3 mm had high sensitivity and specificity and was an independent predictor.

DIAGNOSTICS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Cellular density and variability in laryngeal and pharyngeal squamous cell carcinoma using confocal laser endomicroscopy

M. Sievert, M. Aubreville, M. Eckstein, K. Mantsopoulos, M. Koch, A. O. Gostian, S. K. Mueller, H. Iro, M. Goncalves

Summary: Confocal laser endomicroscopy (CLE) is used to examine the architectural differences at the cellular level between mucosa and squamous cell carcinoma (SCC). Analysis of 60 CLE sequences revealed significant differences in cell size and count between SCC cells and healthy epithelial cells, highlighting the importance of these features in identifying SCC.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES (2023)

添加到收藏夹

Meeting Abstract Urology & Nephrology

Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A study of the EAU Young Academic Urologists urothelial carcinoma working group

G. Marcq, W. Kassouf, M. Roumiguie, B. Pradere, S. Albisinni, A. Cimadamore, J. Y. Teoh, M. Moschini, E. Laukhtina, A. Mari, F. Soria, A. Gallioli, J. B. Beauval, E. Xylinas, D. Pouessel, P. Sargos, G. Ploussard

EUROPEAN UROLOGY (2023)

添加到收藏夹

Meeting Abstract Urology & Nephrology

Impact of pT-stage at second transurethral resection on recurrence and progression risk dynamics in a contemporary series of high-grade T1 bladder carcinoma treated with adequate bacillus Calmette-Guerin: Implications for management

J. D. Subiela Henriquez, W. Krajewski, G. Basile, D. A. Gonzalez-Padilla, J. Aumatell, A. Gallioli, M. Akand, L. Nowak, A. Tukiendorf, B. Pradere, J. Gomez Rivas, M. Moschini, A. Artiles Medina, J. Brasero Burgos, A. Sanchez-Gonzalez, G. Ploussard, F. Montorsi, A. Cimadamore, D. D'andrea, E. Laukhtina, G. Simone, T. Szydelko, M. A. Jimenez Cidre, F. J. Burgos Revilla

EUROPEAN UROLOGY (2023)

添加到收藏夹

Review Pathology

News in the classification of WHO 2022 bladder tumors

Maria Rosaria Raspollini, Eva M. Comperat, Antonio Lopez-Beltran, Rodolfo Montironi, Alessia Cimadamore, Toyonori Tsuzuki, George J. Netto

Summary: The fifth edition of WHO Classification of Tumors series for urinary and male genital tract tumors has been published after six years of the fourth edition. New treatment approaches and molecular data on urological cancers have been implemented during these years. Although morphology remains the basis for taxonomy, a molecular approach and new therapeutic modalities like immunotherapy are emerging. More data is required for the application of these advances in routine pathology practice and patient management.

PATHOLOGICA (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.